"Eli Lilly Cuts 4Q Sales Outlook After Sluggish Growth for Incretin Drugs," published at 10:06 a.m. ET, incorrectly said the outlook was around $400 below the low end of its last estimated range ...

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average ( ^DJI 0.78%) had just a ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly said it received Food and Drug Administration approval ...

Eli Lilly has agreed to acquire Scorpion Therapeutics' breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

Eli Lilly (LLY) stock sinks after cutting its fourth quarter revenue guidance, expecting its GLP-1 weight-loss drug sales to fall below expectations. To watch more expert insights and analysis on ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed ... Image source: Getty Images. Eli Lilly (NYSE: LLY) is the maker of one of today's ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...